Abivax (ABVX) held its annual general meeting on June 6, 2025, where shareholders approved all proposed resolutions. Key approvals included the 2024 financial statements, compensation policies for executives and directors, and financial transaction delegations to the Board. The meeting also ratified the appointments of Sylvie Gr茅goire as Chairman and Dominik H枚chli, MD as a Board member. Abivax, a clinical-stage biotech company, focuses on developing therapeutics that leverage natural regulatory mechanisms to modulate inflammatory responses in chronic inflammatory diseases.
Abivax (ABVX) ha tenuto l'assemblea generale annuale il 6 giugno 2025, durante la quale gli azionisti hanno approvato tutte le risoluzioni proposte. Tra le approvazioni principali figurano il bilancio finanziario del 2024, le politiche di compenso per dirigenti e amministratori e le deleghe per operazioni finanziarie al Consiglio di Amministrazione. L'assemblea ha inoltre ratificato le nomine di Sylvie Gr茅goire come Presidente e di Dominik H枚chli, MD, come membro del Consiglio. Abivax, una societ脿 biotech in fase clinica, si concentra sullo sviluppo di terapie che sfruttano i meccanismi regolatori naturali per modulare le risposte infiammatorie nelle malattie infiammatorie croniche.
Abivax (ABVX) celebr贸 su junta general anual el 6 de junio de 2025, donde los accionistas aprobaron todas las resoluciones propuestas. Las aprobaciones clave incluyeron los estados financieros de 2024, las pol铆ticas de compensaci贸n para ejecutivos y directores, y las delegaciones de transacciones financieras al Consejo. La reuni贸n tambi茅n ratific贸 los nombramientos de Sylvie Gr茅goire como Presidenta y de Dominik H枚chli, MD, como miembro del Consejo. Abivax, una empresa biotecnol贸gica en etapa cl铆nica, se enfoca en desarrollar terapias que aprovechan los mecanismos regulatorios naturales para modular las respuestas inflamatorias en enfermedades inflamatorias cr贸nicas.
Abivax (ABVX) a tenu son assembl茅e g茅n茅rale annuelle le 6 juin 2025, lors de laquelle les actionnaires ont approuv茅 toutes les r茅solutions propos茅es. Parmi les approbations cl茅s figuraient les 茅tats financiers 2024, les politiques de r茅mun茅ration des dirigeants et administrateurs, ainsi que les d茅l茅gations relatives aux op茅rations financi猫res au Conseil d'administration. L'assembl茅e a 茅galement ratifi茅 les nominations de Sylvie Gr茅goire en tant que Pr茅sidente et de Dominik H枚chli, MD, en tant que membre du Conseil. Abivax, une soci茅t茅 biotechnologique en phase clinique, se concentre sur le d茅veloppement de th茅rapies exploitant les m茅canismes r茅gulateurs naturels pour moduler les r茅ponses inflammatoires dans les maladies inflammatoires chroniques.
Abivax (ABVX) hielt am 6. Juni 2025 seine j盲hrliche Hauptversammlung ab, bei der die Aktion盲re alle vorgeschlagenen Beschl眉sse genehmigten. Zu den wichtigen Genehmigungen geh枚rten der Finanzbericht 2024, Verg眉tungsrichtlinien f眉r F眉hrungskr盲fte und Direktoren sowie finanzielle Transaktionsvollmachten f眉r den Vorstand. Die Versammlung best盲tigte au脽erdem die Ernennungen von Sylvie Gr茅goire als Vorsitzende und Dominik H枚chli, MD, als Vorstandsmitglied. Abivax, ein biotechnologisches Unternehmen in der klinischen Entwicklungsphase, konzentriert sich auf die Entwicklung von Therapeutika, die nat眉rliche Regulationsmechanismen nutzen, um Entz眉ndungsreaktionen bei chronisch-entz眉ndlichen Erkrankungen zu modulieren.
Positive
None.
Negative
None.
Abivax Announces Results of its June 6, 2025 Annual General Meeting
PARIS, France, June 11, 2025, 10:00 p.m. CEST 鈥� Abivax SA (Euronext Paris: FR0012333284 鈥� ABVX / Nasdaq 鈥� ABVX) (鈥淎bivax鈥� or the 鈥淐ompany鈥�), a clinical-stage biotechnology company focused on developing therapeutics that harness the body鈥檚 natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, held its annual general meeting of shareholders on June 6, 2025 (the 鈥淕eneral Meeting鈥�), which was chaired by Ms. Sylvie Gr茅goire Chairman of the Board of Directors of Abivax (鈥淏oard鈥�).
The shareholders have adopted all the resolutions proposed by the Board, and particularly the financial statements for the 2024 financial year, the compensation policy applicable to the Chairman, the Chief Executive Officer and the directors, as well as delegations granted to the Board related to financial transactions.
The shareholders have also ratified the appointment of Sylvie Gr茅goire as Chairman and the appointment of Dominik H枚chli, MD as a Board member.
Details of the vote results will be available on the Company鈥檚 website ().
About Abivax Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body鈥檚 natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax鈥檚 lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. More information on the Company is available at www.abivax.com. Follow us on LinkedIn and on X, formerly Twitter, @ABIVAX.
What were the key resolutions approved at Abivax's (ABVX) 2025 annual general meeting?
Shareholders approved the 2024 financial statements, compensation policies for executives and directors, and delegations for financial transactions to the Board. They also ratified appointments of Sylvie Gr茅goire as Chairman and Dominik H枚chli as Board member.
Who is the new Chairman of Abivax (ABVX) confirmed in the 2025 annual meeting?
Sylvie Gr茅goire was confirmed as the Chairman of Abivax's Board of Directors during the June 6, 2025 annual general meeting.
What is Abivax's (ABVX) main business focus?
Abivax is a clinical-stage biotechnology company that develops therapeutics targeting natural regulatory mechanisms to modulate inflammatory responses in chronic inflammatory diseases.
When and where was Abivax's (ABVX) 2025 annual general meeting held?
Abivax's annual general meeting was held on June 6, 2025 in Paris, France.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
